PPAR and functional foods: Rationale for natural neurosteroid-based interventions for postpartum depression

Francesco Matrisciano, Graziano Pinna*

The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois Chicago (UIC), Chicago, IL, USA

ARTICLE INFO

Keywords:
Postpartum depression
Brexlanolone
Neurosteroids
Functional foods
Allopregnanolone
PPAR

ABSTRACT

Allopregnanolone, a GABAergic neurosteroid and progesterone derivative, was recently approved by the Food and Drug Administration for the treatment of postpartum depression (PPD). Several mechanisms appear to be involved in the pathogenesis of PPD, including neuroendocrine dysfunction, neuroinflammation, neurotransmitter alterations, genetic and epigenetic modifications. Recent evidence highlights the higher risk for incidence of PPD in mothers exposed to unhealthy diets that negatively impact the microbiome composition and increase inflammation, all effects that are strongly correlated with mood disorders. Conversely, healthy diets have consistently been reported to decrease the risk of peripartum depression and to protect the body and brain against low-grade systemic chronic inflammation. Several bioactive micronutrients found in the so-called functional foods have been shown to play a relevant role in preventing neuroinflammation and depression, such as vitamins, minerals, omega-3 fatty acids and flavonoids. An intriguing molecular substrate linking functional foods with improvement of mood disorders may be represented by the peroxisome-proliferator activated receptor (PPAR) pathway, which can regulate allopregnanolone biosynthesis and brain-derived neurotropic factor (BDNF) and thereby may reduce inflammation and elevate mood.

Herein, we discuss the potential connection between functional foods and PPAR and their role in preventing neuroinflammation and symptoms of PPD through neurosteroid regulation. We suggest that healthy diets by targeting the PPAR-neurosteroid axis and thereby decreasing inflammation may offer a suitable functional strategy to prevent and safely alleviate mood symptoms during the perinatal period.

1. Introduction

In the pathogenesis of mood disorders, including major depressive disorder (MDD) and postpartum depression (PPD), both neuroinflammation and glutamate-mediated excitotoxicity mechanisms (neuronal death through glutamate-based over-activated stimulation) have been suggested to play a key role (Gerhard et al., 2016; Haroon and Miller, 2017; Leonard, 2018).

Neurosteroids, and specifically allopregnanolone and its isomer pregnanolone, act as endogenous potent, positive, allosteric modulators of the action of γ-aminobutyric acid (GABA) at GABA type A (GABA_A) receptors (Puia et al., 1990; Majewska et al., 1986; Pinna et al., 2000). In addition, sulfated forms of these neurosteroids (e.g., pregnanolone sulfate) influence glutamatergic activity by inhibiting tonic N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission, thereby providing neuroprotection (Vyklický et al., 2016; Tuem and Atey, 2017). Alterations in GABAergic/glutamatergic system may play a pivotal role in the molecular mechanisms underlying PPD (Walton and Maguire, 2019). Interestingly, allopregnanolone reduces calcium influx through the activation of GABA_A receptors expressed on cerebrocortical nerve terminals leading to decreased glutamate release and glial activation, supporting neuroprotective effects (Chang et al., 2019; Noorbakhsh et al., 2014; Lee et al., 2011). Moreover, evidence showed allopregnanolone inhibits the L-type calcium channel activation-evoked glutamate release in the medial prefrontal cortex (Hu et al., 2007).

Neuroactive steroids can be synthesized peripherally from steroid hormone precursors, such as progesterone, or can be synthesized de novo in the brain starting from the conversion of cholesterol to pregnenolone in glial cells (Fig. 1). Pregnenolone, which is taken up by neurons can be further metabolized to progesterone and by the rate-limiting step enzymes, 5α-reductase Type 1 (5α-R1) and 3α-hydroxysteroid dehydrogenase (3α-HSD) to allopregnanolone (Agis-Balboa et al., 2006, 2007; Melcangi et al., 2011; reviewed in Pinna et al., 2008). Locally produced allopregnanolone is responsible for the fine-tuning of GABA_A receptors in corticolimbic glutamatergic neurons (Pinna et al., 2000), a mechanism that has been linked with...

* Corresponding author. University of Illinois at Chicago (UIC), Department of Psychiatry, 1601 West Taylor Street, Chicago, IL, 60612, USA.

E-mail addresses: gpinna@uic.edu, graziano_pinna@yahoo.com (G. Pinna).

https://doi.org/10.1016/j.ynstr.2020.100222

Received 24 January 2020; Received in revised form 23 March 2020; Accepted 8 April 2020

Available online 19 April 2020

2352-2895/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
improvement of behavioral dysfunction (Agis-Balboa et al., 2007; Pinna et al., 2008). At this level, allopregnanolone may conceivably dampen neuroinflammatory processes following activation of glial-type GABA<sub>A</sub> receptors. Recent evidence shows allopregnanolone, following activation of α2-containing GABA<sub>A</sub> receptors and subsequent inhibition of toll-like receptor 4, can regulate the immune response by inhibiting proinflammatory processes (Fig. 1) (Noorbakhsh et al., 2014; Li et al., 2016; Balan et al., 2019).

The recent US Food and Drug Administration (FDA)-approval of the allopregnanolone-based compound, brexanolone, commercially called Zulresso™ for PPD treatment represents an exciting breakthrough for PPD management and opens the field of translational psychiatry to a new generation of neurosteroid-based therapeutics (Leader et al., 2019). These novel agents are characterized by a rapid and long-lasting pharmacological effect after a short-course treatment (reviewed in Zorumski et al., 2019; Meltzer-Brody and Kanes, 2020). Before brexanolone approval, PPD was mainly treated with psychotherapy for mild-to-moderate cases and selective serotonin reuptake inhibitor (SSRI) antidepressants for the management of severe cases, which are associated with low efficacy and significant side effects (reviewed in Anderson and Maes, 2013, and Pinna, 2015; Howard et al., 2017; Sie et al., 2012). Most importantly, the pharmacological effects of SSRIs
Only appear after several weeks, which leaves few options for the management of severe PPD. Often, mothers who present suicidal ideation and negative thoughts against self and the baby need to be hospitalized during the lag of time between the start of SSRI treatment and the onset of the beneficial pharmacological effects. This often results in high hospitalization costs and management problems for babies and families (De Crescenzo et al., 2014).

Indeed, PPD, whose prevalence is estimated between 10% and 15%, is a mild-to-severe psychiatric condition characterized by the presence of depressed mood, anxiety, sleep disorder, cognitive dysfunction and emotional liability that may begin during pregnancy and/or after birth and lasting for several weeks or months after delivery. According to a Center for Disease Control (CDC) study, 1 in 9 women experience symptoms of PPD and prevalence can be as high as 1 in 5 women (Ko et al., 2017; Shorey et al., 2018). Risk factors include history of depressive symptoms, neurotic personality traits, lower social support, lower socioeconomic status, obstetric complications, and major life negative events, trauma and/or stressors during pregnancy (Hirst and Monier, 2010; Rasmussen et al., 2017). If left untreated, PPD may lead to serious health consequences, including child psychological development dysfunction and suicidal behaviors. In addition, women with PPD have higher risk for alcohol abuse compared with women who were neither pregnant nor postpartum (Chapman and Wu, 2013) and alcohol intake has also been associated with peripheral inflammation and neuroinflammation (Orio et al., 2019). In addition, recent evidence suggests that an unhealthy dietary pattern increases the risk of systemic low-grade inflammation and neuroinflammation associated with PPD (Ellsworth-Bowers and Corwin, 2012; Osborne and Monk, 2013; van Bussel et al., 2013; Brites and Fernandez, 2015; Serati et al., 2016; Spencer et al., 2017; Sparling et al., 2017; Melo et al., 2019; Samodien et al., 2019; Popa-Wagner et al., 2020).

Brexanolone, despite its proven high efficacy, showed adverse effects such as headache, dizziness, somnolence, and, in some cases, excessive sedation, which may complicate the safety of its use (Leader et al., 2019). Developing alternative neurosteroid-based interventions may improve PDD management more safely. In this review, we will focus on the role of allopregnanolone in the inflammatory response that may play a relevant role for the onset of depression, as well as the role of functional food-containing bioactive compounds, that show anti-inflammatory effects and may potentially benefit the management of perinatal depression. New findings show that peroxisome-proliferator activated receptor (PPAR)-α, a ligand-activated transcription factor, which is widely distributed in the mammalian central nervous system (CNS), exhibits anti-inflammatory effects (reviewed by Bougarne et al., 2018). Together with PPAR-γ, PPAR-α is deeply involved in several physiological and pathological conditions, including regulation of mitochondrial and proteasomal function, neuroinflammation, oxidative stress and neurodegeneration, which are considered key pathogenetic mechanisms involved in stress-related disorders, including anxiety and depression (discussed in Locci and Pinna, 2019; Esmaili et al., 2016; Agarwal et al., 2017; D’Orio et al., 2018). Intriguingly, PPAR mediates anti-inflammatory responses under several pathophysiological conditions and can stimulate biosynthesis of neurosteroids, such as allopregnanolone, with documented anti-inflammatory actions and role in improving mood symptoms, which suggests that the PPAR-neurosteroid axis may have a pivotal function in the modulation of mood by regulating inflammatory processes. Hence, a specific focus of this article is devoted on the role of PPAR-α in inflammation when we discuss whether its regulation by functional food-containing active micronutrients, by enhancing allopregnanolone biosynthesis, may benefit prevention and treatment of psychiatric disorders, and specifically PPD.
2. PPAR and inflammation: A role for neurosteroids

Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) activation and production of proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, prostaglandins, nitric oxide (NO) and reactive oxygen species (ROS) is regarded as a leading mechanism for local and systemic inflammation. PPAR-α and PPAR-γ are widely distributed in several mammalian organs and tissues and in several areas of the CNS. They mediate several physiological and pathological processes, such as neuroinflammation, regulation of mitochondrial and proteasomal dysfunction, oxidative stress, neurodegeneration, and neuronal differentiation (Moreno et al., 2004; Fidalco et al., 2014).

PPAR-γ is highly expressed in adipocytes and its synthetic agonists have been initially studied as insulin-sensitizing drugs for type-2 diabetes and metabolic syndrome treatment (Botta et al., 2018; Mirza et al., 2019). PPAR-γ is also expressed in microglia and astrocytes and plays a major anti-inflammatory role and it is investigated as molecular target for different neurodegenerative diseases, such as brain damage, cerebral ischemia, Parkinson’s and Alzheimer’s diseases (Combs et al., 2000; Carta and Pisanu, 2013). Its activation, induced by the natural ligand 15-deoxy-d12,14-prostaglandin J2 (15dPGJ2) or synthetic agonists (i.e., pioglitazone), results in a decrease in proinflammatory cytokine production as well as cyclooxygenase-2 (COX-2) through the inhibition of NFκB signaling pathway (Kaundal and Sharma, 2010; Du et al., 2011; Cheng et al., 2019). In brain, PPAR-γ is involved in the regulation of inflammatory-related gene expression on activated microglia, through which it mitigates neuroinflammatory processes under neuronal insults (Villapol, 2018). Thus, PPAR-γ, together with PPAR-α, is a suitable pharmacological target to treat inflammatory-derived neuropsychiatric conditions, including MDD and PPD.

Intriguingly, PPAR-α activation stimulates the biosynthesis of allopregnanolone that in addition to elevating mood, has also been associated with neuropsychiatric conditions, including MDD and PPD. This process leads to a decreased release of pro-inflammatory neurotoxicity (Lee et al., 2011). This resulted in NFκB inhibition (reviewed in Tufano and Pinna, 2020 and depicted in Fig. 1). Allopregnanolone’s binding at GABA<sub>A</sub> receptors on mononcytoid cells leads to diminished production of inflammatory mediators by these cells (Noorabakhsh et al., 2014). Further, GABA suppresses astrocytes and microglia inflammatory responses to lipopolysaccharide (LPS) and INF-γ by inhibiting the NFκB activation pathway and P38 MAP kinase (Lee et al., 2011). This process leads to a decreased release of pro-inflammatory cytokines, such as TNF-α and IL-6 and results in an attenuation of neurotoxicity in vitro (Lee et al., 2011). Interesting, similar anti-inflammatory effects were observed following the administration of the GABA<sub>A</sub> receptor agonist, muscimol and the GABA<sub>A</sub> receptor agonist, baclofen, suggesting the direct role of both types of GABA receptors in reducing neuroinflammation. Interestingly, GABA<sub>A</sub> receptors are also expressed in macrophages and lymphocytes T cells and their activation produces anti-inflammatory effects (Reyes-Garcia et al., 2007; Bhat et al., 2010). In addition, neuroinflammation-associated release of glutamate from activated microglia has been implicated in the progression of neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease and recent studies have shown that PPARs can modulate neurotoxicity by inhibiting glutamate release in LPS-activated microglia (Lee et al., 2018).

This evidence collectively supports the hypothesis of a GABAergic/glutamatergic neurotransmission dysregulation as potential molecular mechanism underlying neuroinflammatory processes, whereby the PPAR family and neurosteroid biosynthesis may play a pivotal role (see Fig. 1). Indeed, recent evidence suggests that neurosteroids regulate neurodegeneration and neuroinflammation supporting neuronal survival either through a direct effect on neurons and/or by decreasing neuroinflammatory responses of microglia and astrocytes (Hong et al., 2018; Arcuri et al., 2017). In vitro and in vivo studies show that 17β-estradiol, progesterone, and allopregnanolone reduce microglial-mediated inflammation (Yilmaz et al., 2019).

Hence, an intriguing molecular player that might link inflammation and neurosteroids is represented by PPAR that has been implicated in the pathology of numerous diseases, such as diabetes, stroke, cancer, obesity and even mood disorders (Stienstra et al., 2007; Liu et al., 2018; Cheng et al., 2019; Tufano and Pinna, 2020).

3. PPAR role in psychiatric disorders and behavioral regulation

PPAR-α and PPAR-γ exert functions, including glucose and lipid metabolism regulation, anti-inflammatory and oxidative stress inhibition, via a direct inhibition of NFκB signaling (Kauppinen et al., 2013; Sakamoto et al., 2016; Marion-Letellier et al., 2016). Moreover, PPAR-γ mediates intestinal anti-inflammatory effects, decreases oxidative stress in brain and increases insulin sensitization (Marion-Letellier et al., 2016). PPARs are key molecular regulators of cell metabolism, energy homeostasis, cellular development, and differentiation; thus, their ligands find several clinical applications, such as hyperlipidemia and hypertriglyceridemia in combination with statins, type-2 diabetes mellitus, metabolic syndrome and non-alcoholic fatty liver disease (Pawlak et al., 2015; Botta et al., 2018; Cheng et al., 2019).

PPAR-α endogenous modulators include palmitoylethanolamide (PEA), oleoylethanolamine (OEA) and stearoylethanolamide (SEA). Specifically, PEA, which was discovered by the Italian Nobel Prize laureate Rita Levi Montalcini in the 90s, is an endogenously synthesized lipid with well described neuroprotective and anti-inflammatory properties (Levi-Montalcini et al., 1996). PEA may play a relevant role in stress-related disorders, including depression and post-traumatic stress disorder (PTSD) (Hillard, 2018). Indeed, the levels of PEA, OEA and SEA are decreased in PTSD patients (Wilker et al., 2016). Both synthetic agonists of PPAR-α and PPAR-γ have been investigated in clinical trials for their ability to improve depression symptoms (reviewed by Tufano and Pinna, 2020; Cheng et al., 2019). A recent clinical trial investigated the role of PEA as add-on therapy for depression showing symptoms improvement in patients with major depressive disorder treated with citalopram (Ghazizadeh-Hashemi et al., 2018). Selective PPAR-γ agonists, rosiglitazone and pioglitazone were originally approved by the FDA for diabetes treatment. These compounds also reduce the response to chronic stress and have been studied in a number of clinical trials that evaluated their efficacy in improving depression symptoms (reviewed by Colle et al., 2017; Tufano and Pinna, 2020). A combined therapy of pioglitazone with the SSRI antidepressant, citalopram, showed a higher pharmacological response and remission rate, and rapid onset compared to citalopram alone (Sepanjnia et al., 2012). In another study, a 12-week pioglitazone administration induced antidepressant effects in patients with comorbid insulin resistance, supporting a link between depression and metabolic dysregulation (Lin et al., 2015).

This evidence suggests that for both PPAR-α and γ, in addition to their anti-cholesterol and anti-diabetic effects, an unforeseen potential therapeutic profile is emerging in the treatment of mood disorders.

4. Functional foods: role in inflammation and PPD

Functional food is defined as “natural or processed food that contain known or unknown biologically-active compounds; which, in defined, effective, and non-toxic amounts, provide a clinically proven and documented health benefit for the prevention, management, or treatment of chronic disease” (Dhiman et al., 2014; Martirosyan and Singh, 2015). A growing body of evidence suggests that many functional foods can modulate inflammation both acutely and chronically through their bioactive compounds and ultimately improve stress-related mood disorders (Alkhathib et al., 2017; Granado-Lorencio and Hernández...
### Table 1

**Functional Foods rich in micronutrients that activate PPAR-α and PPAR-γ and induce pharmacological effects.**

| Phytochemical | Bioactive Compound | Food Source | Physiological effects |
|---------------|--------------------|-------------|----------------------|
| Flavonoids    | Flavonols          | Berries, kale, grapes, spinach, bell peppers, onions, broccoli, red cabbage, red and green bell peppers, pomegranate, kiwi, tomatoes, oranges, lemons, apples, strawberries, blueberries | Anti-oxidative, anti-inflammatory, anti-carcinogenic, neuroprotective, reduction in CVD, reduction in blood pressure |
|               | Kaempferol, Myricetin, Quercetin | Berries, kale, grapes, spinach, bell peppers, cocoa, broccoli, sweet potatoes, tomatoes, capers | Anti-carcinogenic, anti-inflammatory, antioxidant, antiviral activities, mitigation of microglia-mediated neuroinflammation |
|               | Berries, kale, grapes, spinach, bell peppers, cocoa, broccoli, sweet potatoes, tomatoes, capers | Anti-carcinogenic, anti-inflammatory, antioxidant, antiviral activities, mitigation of microglia-mediated neuroinflammation |
|               | Hesperetin, Naringenin | Citrus fruits (lemons and oranges), grapes | Antioxidant, anti-inflammatory |
|               | Flavones           | Celery, fresh parsley, olives, oregano, peppers and rosemary | Suppression of oxidative stress via anti-inflammatory effect on NF-κB, brain support, protection and memory increase |
|               | Apigenin, Luteolin  | Celery, fresh parsley, olives, oregano, peppers and rosemary | Suppression of oxidative stress via anti-inflammatory effect on NF-κB, brain support, protection and memory increase |
|               | Epicatechin-gallates, Procyanidins, Catechin | Tea, grapes, lentils, cocoa, apples with peel on, apricots, cherries, peaches, blackberries, black grapes, strawberries, blueberries and raspberries | Antioxidant, free radical scavenging properties, decrease of the hypothalamic inflammation and microglia overactivation, improvement in cognitive function, activities, and cognitive function |
|               | Daidzein           | Grape seeds, soy products | Improve in adipose inflammation and insulin resistance |
|               | Genistein          | Soybeans | Antioxidant and neuroprotective activities, improve in glucose metabolism and cognitive function |
|               | Caffeic acid, Ferulic acid | Apples, coffee beans, blueberries, oranges, peaches, potatoes, peas and beans | Antioxidant and anti-inflammatory properties, protection and memory increase, prevention of neurodegeneration |
|               | Caffeic acid, Ferulic acid | Apples, coffee beans, blueberries, oranges, peaches, potatoes, peas and beans | Antioxidant and anti-inflammatory properties, protection and memory increase, prevention of neurodegeneration |
|               | Gallate acid, Oligomeric acid | Green tea, tea leaves, black tea, green beans, black beans, barley, peas, beans, lentils, rice, potatoes, tomatoes, and potatoes | Antioxidant and anti-inflammatory properties, protection and memory increase, prevention of neurodegeneration |
|               | Resveratrol        | Grape skin, peanuts, red wine, cranberries | Anti-aging, chemo-preventive, anti-inflammatory, anti-carcinogenic, anti-atherosclerotic, anti-inflammatory, anti-neurodegenerative, microglia inhibition |
|               | Tannins/Proanthocyanidins | Coffee, cocoa, lentils, peas, walnuts, berries, olives, plums, prunes, raisins, grapes, strawberries, and rosehips | Antioxidant properties, neuroprotective effects |
|               | Curcumin           | Turmeric plants | Antioxidant and anti-inflammatory activities |

**References**

Wang et al. (2014); Botta et al. (2018); Mozaffarian et al. (2018); Ward et al. (2018).

Vallee et al. (2017); Expo et al. (2019).

Nepal et al. (2019).

Portiere et al. (2019).

Mallia et al. (2016).

Liu et al. (2020); Abdel-Moneim et al. (2018); Georgiadis et al. (2015).

Peritore et al. (2019).

Vallée et al. (2017); Esposito et al. (2011).

D’Orio et al. (2018).

Ishikawa et al. (2018).

Ito et al. (2018).

F. Matrisciano and G. Pinna

Neurobiology of Stress 12 (2020) 100222
Alvarez, 2016; Spagnuolo et al., 2018). In fact, diet represents a major modifiable risk factor that modulate the immune system reactivity and a suitable strategy to fight against systemic low-grade inflammation, which is now strongly considered to be involved in the pathogenesis of several chronic diseases, including cardiovascular disease, obesity, diabetes, autoimmune diseases, neurodegenerative diseases, and mood disorders (Libby, 2007; Berk et al., 2013; Cox et al., 2015).

Bioactive compounds, such as flavonoids, essential fatty acids, minerals, vitamins, and phytonutrients are essential for overall health and to prevent, manage or treat chronic diseases, including metabolic disorders, diabetes, cardiovascular diseases and hypertension, or pathologies affecting the CNS, including mood disorders (Simopoulos, 2008; Zhang et al., 2015; Pérez-Gano and Castell, 2016; Mozaffarian and Wu, 2018). Increasing evidence indicates that neuroinflammation represents a key biological component in the pathogenesis of psychiatric disorders (Brites and Fernandes, 2015; Benatti et al., 2016; Maeng and Hong, 2019). Based on the role of inflammation in depressive disorders, including PPD (Payne and Maguire, 2019), as well as the finding from recent clinical studies that have evaluated the efficacy of changes in diet in improving depressive symptoms (Molendijk et al., 2018), we propose that integrating PPD management with functional foods rich in anti-inflammatory micronutrients might represent an innovative strategy for improving the overall clinical outcome.

PPD shares the same diagnostic criteria as MDD, although the cause of PPD remains more obscure. As in MDD, a combination of environmental and biological factors may occur, including family history, stressful events, unhealthy diet and genetic risk factors (Payne and Maguire, 2019). Moreover, in PPD, a rapid drop in progesterone levels after delivery is considered one of the major risk factors (Schiller et al., 2015). Attenuating this dramatic hormonal change might be helpful to avoid severe clinical consequences. Nutrition plays a biological role in depression, especially during pregnancy and lactation during which micronutrients, such as vitamins, minerals, essential fatty acids, and antioxidants become depleted and may play a role in the development of perinatal depression. Some of these nutrients are essential fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), vitamin D, B-vitamins (specifically B6, B9, B12), and trace minerals (like zinc, iron, and selenium) (Amini et al., 2019; Sauer and Grabrucker, 2019).

Omega-3 fatty acids have well-known anti-inflammatory and anti-allergic activity, predominantly through the inhibition of excessive immune responses. EPA- and DHA-derived resolvins and protectins actively ameliorate a pro-inflammatory condition. Polysaturated fatty acids (PUFAs) are highly concentrated in neural phospholipids and are important components of the neuronal cell membrane and play a pivotal role in enhancing synaptic plasticity and neuronal communication (Pérez et al., 2017). Resolvins and protectins belong to the class ofPUFA metabolites, which exert anti-inflammatory activity that regulate the synthesis and release of pro-inflammatory mediators (Joffre et al., 2019). DHA and EPA exert different functions, such as maintaining cell-membrane fluidity, inhibiting inflammatory processes by decreasing secretion of proinflammatory cytokines. Foods rich in omega-3 PUFAs are walnuts, sunflower seeds, flax seeds and oil and fatty fish, such as salmon. A recent meta-analysis conducted by Lin et al. (2017) suggests a potential role of PUFA s for perinatal depression treatment (Lin et al., 2017). Previous studies have reported controversial results on the beneficial effects of omega-3 fatty acids for perinatal depression treatment in part due to flaws in study design (Freeman et al., 2008; Rees et al., 2008). However, a randomized, double-blind, placebo-controlled trial showed that omega-3 improved depressive symptoms (Su et al., 2008).

The main anti-inflammatory properties of flavonoids include suppressing release of cytokines, such as IL-1β and TNF-α, from activated microglia (Fig. 1). They may also affect inducible NO synthase regulation and inhibit the activation of NADPH oxidase, and down-regulate the activity of pro-inflammatory transcription factors, such as NFκB, that play a key role in the intestinal inflammatory response (Atrey et al., 2008). Green tea, broccoli, onions, and berries are enriched in phytonutrients, such as carotenoids, ellagic acid, flavonoids, resveratrol, glucosinolates, and phytoestrogens that help fighting oxidation and inflammation. Naringenin, quercetin, hydrocaffeic acid, procyanidins, and anthocyanidins (Table 1) belong to the class of flavonoids and exert anti-inflammatory effects in vivo and in vitro by inhibiting the expression of iNOS, ICAM-1, MCP-1, COX-2, TNF-α, IL-1β and IL-6 expression (Chen et al., 2018; Gil-Cardoso et al., 2016; discussed in Matrisciano and Pinna, 2019).

Another bioactive compound relevant for brain functioning is vitamin D. Vitamin D belongs to the class of fat-soluble vitamins along with vitamin A, E and K. It is considered a steroid hormone, mostly known for its role in calcium metabolism and its ability to increase the absorption of calcium and phosphorus from the intestine (Cui et al., 2017). However, vitamin D exerts many other biological effects including processes involved in brain development and neuronal activity (Eyles et al., 2011). Deficiency in vitamin D is considered a risk factor for neuropsychiatric disorders, including PPD, MDD and schizophrenia (Amini et al., 2020; Szpunar, 2019; Zhu et al., 2019; McGrath et al., 2010). It causes alterations in brain structure and in dopamine and glutamate signaling. Major dietary sources of vitamin D are salmon, shrimp, herring and sardines, egg yolks and mushrooms (Matrisciano and Pinna, 2019). Zinc is an essential trace mineral required for all physiological systems, including neural functioning and proper cellular function, such as DNA replication, transcription, protein synthesis, maintenance of cell membranes, cellular transport, as well as endocrine, immunological and neuronal systems. Zinc is found mainly in red meat, poultry, fish, and dairy. Dysregulation of zinc is associated with reduced immunological functioning, alterations in cognitive performance, gastrointestinal complaints (Bonaventura et al., 2015). Lower zinc levels can be a consequence of inflammation or nutritional deficiencies and it helps to modulate the hyper-glutamatergic state associated with depression (Wang et al., 2018). Approximately 20% of dietary zinc intake is used by intestinal bacteria supporting the major role of a healthy microbiome in brain function (Sauer and Grabrucker, 2019). In addition, zinc modulates PPAR-γ signaling, which is impaired in zinc deficiency (Meerarani et al., 2003).

5. A natural strategy to potentiate the PPAR-neurosteroid axis and improve mood

Dietary fatty acids have been implicated in immune and inflammatory processes by regulating NFκB and PPAR-α and γ transcription factor pathways (Calder, 2013). In rodents, for instance, high-fat diets alter PPAR pathway causing abnormalities in the microbiome that can be reversed by resoligizatone, a PPAR-γ agonist (Tomas et al., 2016). Several natural bioactive compounds act on PPARs, including the tea plant, soybeans, palm oil, ginger, grapes and wine as well as a number of culinary herbs and spices (e.g. Origanum vulgare, Rosmarinus officinalis, Salvia officinalis, Thymus vulgaris) (reviewed by Wang et al., 2014). Curcumin has also shown anti-inflammatory and antioxidant effects by increasing PPAR-γ activity (Li et al., 2017). OEA, which is a natural metabolite of oleic acid, and an endogenous PPAR-α modulator, shows anti-inflammatory activity (Yang et al., 2016). Then, foods rich in oleic acid, such as olive oil, avocado and almond oil can be used as part of the anti-inflammatory dietary patterns. In addition, omega-3 (or n-3) PUFAs and their metabolites are natural ligands for PPAR-γ (Table 1). PUFA s affect the neuroendocrine-immune axis of depression through their activity on inflammatory responses (Bhathena, 2006; Marion-Letellier et al., 2015). EPA and DHA supplementation have been shown to decrease levels of key inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8 (Zhao et al., 2004). Recently, a major role in improving symptoms of depression and anxiety in patients or in elevating mood in healthy individuals was shown in populations that were fed with a Mediterranean-based diet, which is rich in fruits, vegetables,
6. Conclusion

The nuclear receptors, PPAR-α and γ appear as novel fascinating targets for the treatment of mood disorders caused by stressful conditions, such as during mood instability and low-grade inflammatory states that occur during pregnancy or after birth. This review focuses on the role of neuroinflammation as a molecular mechanism underlying mood disorders, including perinatal depression and highlights the potential impact of PPAR regulation in these processes. We addressed the possibility that by downregulating inflammatory processes, following activation of PPAR with a healthy diet rich in PPAR-bioactive micro-nutrients found in functional foods, may help preventing, managing and treating mood disorders. These ligands by stimulating anti-inflammatory mechanisms and, possibly, by enhancing neurosteroid biosynthesis, may provide a future, more natural and safe approach to prevent and alleviate pathophysiological processes that lead to perinatal depression and other mood disorders.

CRediT authorship contribution statement

Francesco Matrisciano: Writing - original draft. Graziano Pinna: Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Visualization, Writing - original draft, Writing - review & editing.

Acknowledgments

This study was supported by the United States Department of Defense Grant W81XWH-15-1-0521 to GP.

References

Abdel-Moneim, A., El-Twab, S.M.A., Youssef, A.L., Rehmat, E.S.A., Ashour, M.B., 2018. Modulation of hyperglycemia and dyslipidemia in experimental type 2 diabetes by gallic acid and P-coumaric acid: the role of adipocytokines and PPARs. Biomed. Pharmacother. 105, 1091–1097.

Amar, S., Yadvir, A., Chaturvedi, R.K., 2017. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem. Biophys. Res. Commun. 483 (4), 1166–1177.

Agis Balboa, R.C., Pinna, G., Zhoubi, A., Malm, E., Veldic, M., Costa, E., et al., 2006. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 103, 14602–14607.

Agis Balboa, R.C., Pinna, G., Pibiri, F., Kudrius, B., Costa, E., Guidotti, A., 2007. Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. Proc Natl Acad Sci U S A 104, 18765–18771.

Almeida, F.B., Gomez, R., Tannhauser Barros, H.M., Nin, M.S., 2019. Hemisphere-dependent changes in mRNA expression of GABA A receptor subunits and BDNF after intra-prefrontal cortex alloppregnanolone infusion in rats. Neuroscience 397, 56–66.

Amini, S., Jafari Rad, S., Roshanzamir, S., Sadeghian, B., Niyaz, A., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Anderson, G., Mues, M., 2013. Postpartum depression: psychoneuroimmunological underpinnings and treatment. Neuropsychiatric Dis. Treat. 9, 277–287.

Arcuri, C., Mecca, C., Bianchi, G., Giambando, L., Donato, A., 2017. The pathophysiological role of microglia in dynamic surveillance, phagocytosis and structural remodeling of the developing CNS. Front. Mol. Neurosci. 10, 191.

Arefian, M., Jafari Rad, S., Amini, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amini, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Amini, S., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amit, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Anderson, G., Mues, M., 2013. Postpartum depression: psychoneuroimmunological underpinnings and treatment. Neuropsychiatric Dis. Treat. 9, 277–287.

Arefian, M., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amini, S., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amit, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Amini, S., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amini, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Anderson, G., Mues, M., 2013. Postpartum depression: psychoneuroimmunological underpinnings and treatment. Neuropsychiatric Dis. Treat. 9, 277–287.

Arefian, M., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amit, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.

Anderson, G., Mues, M., 2013. Postpartum depression: psychoneuroimmunological underpinnings and treatment. Neuropsychiatric Dis. Treat. 9, 277–287.

Arefian, M., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amini, S., Jafari Rad, S., Amani, R., 2019. Postpartum depression and vitamin D: a systematic review. Crit. Rev. Food Sci. Nutr. 59, 1514–1520.

Amit, S., Amani, R., Jafari Rad, S., Czerghazhi, M., Sanyah, M., Hennai, A.A., 2020. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 3, 1–11.
induced neuroinflammation and depression. CNS Neurol. Disord. - Drug Targets 15, 414–433.
Berke, M., Williams, J., Jacka, F.N., O’Neill, A., Pasco, J.A., Moynan, S., et al., 2013. So depression is an inflammatory disease, but where does the inflammation come from? Med. Hypotheses 81, 101–106.
Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tisen, R.W., et al., 2010. Inhibitory role for GABA in autoimmune innervation. Proc. Natl. Acad. Sci. U.S.A. 107, 25855.
Ibáñez, S.J., 2006. Relationship between fatty acids and the endocrine and neuroendocrine system. Nutr. Neurosci. 9 (1-2), 1–10. https://doi.org/10.1080/10284150600627128.
Bonaventura, P., Benedetti, A., Galbareda, F., Mirozes, P., 2015. Zinc and its role in immunity and inflammation. Autoimmun. Rev. 14, 277–285.
Botta, M., Audano, M., Salehbak, A., Sirtori, C.R., Mitro, N., Ruschina, M., 2018. PPAR agonists and metabolic syndrome: an established role? Int. J. Mol. Sci. 19 (4).
Bougarne, N., Weyers, B., Desmet, S.J., Deckers, J., Ray, D.W., Staels, B., et al., 2018. Microglia and alcohol meet at the crossroads: microglia as critical modulators of alcohol neurotoxicity. Toxicol. Lett. 283, 21–31.
Bomhof, J.I., 2000. Introduction to functional food science: textbook. In: second ed. Functional Food science and technology. Food and Health: Functional Foods (Food and Health: Functional Foods), pp. 89–92.
Bhathena, S.J., 2006. Relationship between fatty acids and the endocrine and neuroendocrine system. Nutr. Neurosci. 9 (1-2), 1–10. https://doi.org/10.1080/10284150600627128.
Bougarne, N., Weyers, B., Desmet, S.J., Deckers, J., Ray, D.W., Staels, B., et al., 2018. Microglia and alcohol meet at the crossroads: microglia as critical modulators of alcohol neurotoxicity. Toxicol. Lett. 283, 21–31.
Bomhof, J.I., 2000. Introduction to functional food science: textbook. In: second ed. Functional Food science and technology. Food and Health: Functional Foods (Food and Health: Functional Foods), pp. 89–92.
activity and reducing oxidative stress. Int. J. Mol. Med. 39, 1307-1316.

Libby, P., 2007. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev. 65 (12 Pt 1), S140-S146.

Lin, K.W., Wroolie, T.E., Robakis, T., Ragon, N.L., 2015. Adjuvant pioglitazone for un-responding depression: clinical correlates of treatment response. Psychiatr. Res. 230, 846-852.

Lin, P.Y., Chang, C.H., Chong, M.F., Chen, H., Su, K.P., 2017. Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis. Biol. Psychiatry 82 (8), 560-569.

Lin, Y., Colby, J.K., Zuo, X., Jouolle, J., Wei, D., Shureiqi, I., 2018. The role of PPAR-δ in polyunsaturated fatty acids and inflammation. Physiol. Rev. 98 (1), 353-384.

Locci, A., Pinna, G., 2017. Allopregnanolone biosynthesis down-regulation and changes in GABA receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. Br. J. Pharmacol. 174, 3226-3241.

Locci, A., Pinna, G., 2019. Stimulation of peroxisome proliferator-activated receptor-α by N-palmitylolethanolamine engages allopregnanolone biosynthesis to modulate emo- tional behavior. Biol. Psychiatry. 85, 1036-1045.

Maeng, S.H., Hong, H., 2019. Inflammation as the potential basis in depression. Int. Neuropsychol. J 23 Suppl. 2, S63-71.

Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L., Paul, S.M., 1986. Steroid metabolism in the perinatal social isolation mouse. Brain Res. 378, 133-141.

Mallik, S.B., Mudgal, J., Nampoothiri, M., Hall, S., Anoopkumar-Dukie, S., Grant, G., Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L., Paul, S.M., 1986. Steroid metabolism in the perinatal social isolation mouse. Brain Res. 378, 133-141.

Meltzer-Brody, S., Kanes, S.J., 2020. Allopregnanolone in postpartum depression: role in neurodevelopment. Neurochemistry 23, 131–145.

Molendijk, M., Molero, P., Ortuño-Sánchez-Pedreño, F., Vander Does, W., 2018. Angelica archangelica root extract improves hippocampal function in mice: a preclinical study. Brain Behav. 8 (11), e0149676.

Noorbakhsh, F., Baker, G.B., Power, C., 2014. Allopregnanolone and neuroinflammation: a role in Alzheimer’s disease. Neurosci. Lett. 632, 218–223.

Pérez-Cano, F.J., Castell, M., 2016. Flavonoids, inflammation and immune system. Nutrients 8 (10).

Periote, A.F., Siracusa, R., Crupi, R., Cuzzocrea, S., 2019. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antidepressant drugs present in distress. Drug Chem. Physiol. 52, 165–180.

Pérez, M.A., Peña-Losada-Sanchez, V., Abumada, J., Fuenzalida, M., Dagnino-Subiabre, A., 2017. n-3 polyunsaturated fatty acid supplementation restored impaired memory and GABAergic synaptic efficacy in the hippocampus of stressed rats. Nutr. Neurosci. 21 (8), 556-569.

Pérez-Cano, F.J., Castell, M., 2016. Flavonoids, inflammation and immune system. Nutrients 8 (10).

Pini, G., Matrisciano and G. Pinna

Neurobiology of Stress 12 (2020) 100222

Texas Web. 3 Apr. 2015.http://functionalfoodscenter.net.
Shorey, S., Chee, C.Y.I., Ng, E.D., Chan, Y.H., Tam, W.W.S., Chong, Y.S., 2018. Prevalence and incidence of postpartum depression among healthy mothers: a systematic review and meta-analysis. J. Psychiatr. Res. 104, 235–248.

Sie, S.D., Wennisik, J.M.R., van Driel, J.J., te Winkel, A.G.W., Boer, K., Casteelen, G., et al., 2012. Maternal use of SSRI’s, SNRI’s and NaSSA: practical recommendations during pregnancy and lactation. Arch. Dis. Child. Fetal Neonatal Ed. 97 (6), F472-F476.

Simopoulos, A.P., 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. 233 (6), 674–688.

Singh, C., Liu, L., Wang, J.M., Irwin, R.W., Yao, J., Chen, S., et al., 2012. Maternal use of SSRIs, SNRI’s and NaSSA: practical recommendations during pregnancy and lactation. Arch. Dis. Child. Fetal Neonatal Ed. 97 (6), F472-F476.

Spagnuolo, C., Moccia, S., Russo, G.L., 2018. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur. J. Med. Chem. 153, 105–115.

Spargur, T.M., Henshke, N., Nesbitt, R.C., Gabrysch, S., 2017. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern. Child Nutr. 13 (1).

Spencer, S.J., D’Angelo, H., Soch, A., Watkins, L.R., Maier, S.F., Barrientos, R.M., 2017. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiol. Aging 33, 1493-1506.

Szpunar, M.J., 2019. Association of antepartum vitamin D deficiency with postpartum depression: a review. Matern. Child Nutr. 13 (1).

Stienstra, R., Duval, C., Müller, M., Kersten, S., 2007. PPARs, obesity, and inflammation. J. Nutr. 137 (5), 1464–1468.

Strobel, F., Matrisciano and G. Pinna 853–866.

Szulc, P., 2016. Protective effects of omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind placebo-controlled trial. J. Clin. Psychiatr. 69 (4), 417–426.

Sturman, K.B., Atey, T.M., 2017. Neuroactive steroids: receptor interactions and responses. Front. Neurosci. 11, 322.

Sparling, T.M., Henschke, N., Nesbitt, R.C., Gabrysch, S., 2017. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern. Child Nutr. 13 (1).

Spencer, S.J., D’Angelo, H., Soch, A., Watkins, L.R., Maier, S.F., Barrientos, R.M., 2017. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiol. Aging 33, 1493-1506.

Spargur, T.M., Henshke, N., Nesbitt, R.C., Gabrysch, S., 2017. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern. Child Nutr. 13 (1).

Spencer, S.J., D’Angelo, H., Soch, A., Watkins, L.R., Maier, S.F., Barrientos, R.M., 2017. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiol. Aging 33, 1493-1506.

Sparling, T.M., Henschke, N., Nesbitt, R.C., Gabrysch, S., 2017. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern. Child Nutr. 13 (1).

Spencer, S.J., D’Angelo, H., Soch, A., Watkins, L.R., Maier, S.F., Barrientos, R.M., 2017. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiol. Aging 33, 1493-1506.

Stienstra, R., Duval, C., Müller, M., Kersten, S., 2007. PPARs, obesity, and inflammation. J. Nutr. 137 (5), 1464–1468.

Strobel, F., Matrisciano and G. Pinna 853–866.

Szulc, P., 2016. Protective effects of omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind placebo-controlled trial. J. Clin. Psychiatr. 69 (4), 417–426.

Sturman, K.B., Atey, T.M., 2017. Neuroactive steroids: receptor interactions and responses. Front. Neurosci. 11, 322.

Sparling, T.M., Henschke, N., Nesbitt, R.C., Gabrysch, S., 2017. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern. Child Nutr. 13 (1).

Spencer, S.J., D’Angelo, H., Soch, A., Watkins, L.R., Maier, S.F., Barrientos, R.M., 2017. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiol. Aging 33, 1493-1506.

Stienstra, R., Duval, C., Müller, M., Kersten, S., 2007. PPARs, obesity, and inflammation. J. Nutr. 137 (5), 1464–1468.

Strobel, F., Matrisciano and G. Pinna 853–866.